PRESS RELEASE, January 2, 2019
Auransa to Present at Biotech Showcase 2019
PALO ALTO, CA – January 2, 2019 – Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical need, today announced that its chief executive officer, Pek Lum, Ph.D., will deliver a corporate presentation at the 11th Annual Biotech Showcase™, being held January 7-9, 2019 at the Hilton San Francisco Union Square in San Francisco.
Details for this presentation are as follows:
Biotech Showcase 2019
Time/Date: 10:30 a.m. PT on Tuesday, January 8, 2019
Location: Hilton San Francisco Union Square
Room: Franciscan – C (Ballroom Level)
Additionally, the Auransa management team will take part in 1-on-1 meetings at the conference. To request a meeting with Auransa at Biotech Showcase 2019, please contact Stephanie Diaz of Vida Strategic Partners at firstname.lastname@example.org.
Founded in 2014, Auransa is an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical need. The company is working to redefine precision medicine by combining a sophisticated, proprietary predictive computational platform with traditional pharmaceutical industry experience. The company’s SMarTR™ Engine, which leverages machine learning, advanced analytics and mathematics in an AI framework generates insights from molecular data for a deep understanding of disease biology and patient subtypes. This information, when paired with the company’s breadth of in-house drug discovery and development expertise, drives the identification of novel compounds designed to most effectively address significant unmet medical needs for clinically meaningful disease subtypes. The company has successfully generated a broad pipeline of drug candidates that are advancing toward investigational new drug (IND) filings. While Auransa is internally focused on oncology, the SMarTR Engine has also generated candidates in the areas of neurology, inflammation, infectious disease and metabolic disease. In addition to the programs being advanced internally, Auransa has also entered into an exclusive regional licensing agreement with a subsidiary of Lee’s Pharmaceutical Holdings Ltd. for the development and commercialization of one of the first programs generated by the SMarTR Engine. For more information, please visit: www.auransa.com.
Vida Strategic Partners
Stephanie Diaz (investors)
Tim Brons (media)
SOURCE: AURANSA, INC.